Varex Imaging earnings release, August 10, 2026

Varex Imaging Corp (VREX) · Form 8-K, Item 2.02 · Filed · SEC filing

VAREX ANNOUNCES FINANCIAL RESULTS FOR

THIRD QUARTER FISCAL YEAR 2026

SALT LAKE

CITY, August 10, 2026 – Varex Imaging Corporation (Nasdaq: VREX) today announced its unaudited financial results for the third quarter fiscal year 2026.

Q3FY26 Summary

"Third-quarter product sales before the IEEPA-related customer reimbursement adjustment were approximately $217 million, reflecting strong growth in Industrial and continued expansion in cargo and vehicle inspection systems,” said Sunny Sanyal, Chief Executive Officer. “The quarter also included the recovery of tariffs that had increased our product costs in prior periods. We generated $21 million of operating cash flow and enter the fourth quarter with continued momentum.”

During the quarter, Varex received refunds totaling $17 million from U.S. Customs related to previously paid IEEPA tariffs. The Company recorded a corresponding $7 million reduction to revenues reflecting an accrual for expected customer reimbursements of previously billed IEEPA tariffs. Together, these items resulted in higher third-quarter gross profit by approximately $10 million.

Third quarter revenues were up 4% year-over-year. Third quarter Medical revenue was $134 million and Industrial revenue was $77 million. Non-GAAP gross margin increased to 37% from 34% in the prior-year quarter, and non-GAAP EPS was $0.31 compared to $0.13 in the third quarter of fiscal year 2025.

Balance Sheet & Cash Flow

Cash, cash equivalents, and marketable securities were $99 million as of the end of the third quarter, compared to $155 million at the end of fiscal year 2025. The change in cash primarily reflects the

Company's debt redemption and refinancing completed in March, as well as increased working capital associated with inventory.

Non-GAAP Financial Measures

*Please refer to

"Reconciliation between GAAP and non-GAAP Financial Measures" below for a reconciliation of non-GAAP items to the comparable GAAP measures.

Cancellation of Earnings Conference Call

In light of the announced transaction with Teledyne Technologies Incorporated, and as is customary during the pendency of such a transaction, Varex has cancelled its earnings conference call for the third quarter of fiscal year 2026 previously scheduled for 3:00 p.m. Mountain Time on August 10, 2026, and will not be providing financial guidance in conjunction with its third quarter fiscal year 2026 earnings release.

About Varex

Varex Imaging Corporation is a leading innovator, designer, and manufacturer of X-ray imaging components, which include X-ray tubes, digital detectors, and other image processing solutions that are key components of X-ray imaging systems, as well as X-ray imaging systems for industrial applications. With a 70+ year history of successful innovation,

Varex’s products are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers incorporate the company’s X-ray sources, digital detectors, connecting devices, and imaging software in their systems to detect, diagnose, protect, and inspect. Headquartered in Salt Lake City, Utah, Varex employs approximately 2,500 people located in North America,

Europe, and Asia. For more information visit www.vareximaging.com.

Forward Looking Statements

This news release contains “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements concerning unaudited financial results; industry or business outlook; product demand environment; and any statements using the terms “believe,” “expect,” “anticipate,”

Financial statements

Income Statement

Three Months Ended — (Unaudited) (In millions, except for per share amounts)

Three Months Ended – July 3, 2026Three Months Ended – July 4, 2025Nine Months Ended – July 3, 2026Nine Months Ended – July 4, 2025
Revenues, netMedical134142.1435440.5
Revenues, netIndustrial76.560.9201.1175.2
Revenues, netTotal revenues210.5203636.1615.7
Cost of revenuesMedical85.795.4290.1288.4
Cost of revenuesIndustrial48.140.1126.9114.6
Cost of revenuesTotal cost of revenues133.8135.5417403
Gross profitMedical48.346.7144.9152.1
Gross profitIndustrial28.420.874.260.6
Gross profitTotal gross profit76.767.5219.1212.7
Operating expenses:Research and development23.321.467.266.9
Operating expenses:Selling, general, and administrative30.632.999.399.3
Operating expenses:Impairment of goodwill93.993.9
Operating expenses:Total operating expenses53.9148.2166.5260.1
Operating expenses:Operating income (loss)22.8-80.752.6-47.4
Operating expenses:Interest income0.92.51.97.5
Operating expenses:Interest expense-5.8-9.4-30.9-27.6
Operating expenses:Other (expense) income, net-1.71-10-5.8
Operating expenses:Interest and other expense, net-6.6-5.9-39-25.9
Operating expenses:Income (loss) before taxes16.2-86.613.6-73.3
Operating expenses:Income tax expense0.32.53.38.8
Operating expenses:Net income (loss)15.9-89.110.3-82.1
Operating expenses:Less: Net income attributable to noncontrolling interests0.20.40.4
Operating expenses:Net income (loss) attributable to Varex15.7-89.19.9-82.5
Net income (loss) per common share attributable to VarexBasic0.37-2.150.24-2
Net income (loss) per common share attributable to VarexDiluted0.37-2.150.23-2
Weighted average common shares outstandingBasic42.141.54241.3
Weighted average common shares outstandingDiluted42.641.542.541.3

Income Statement

Three Months Ended — (Unaudited) (In millions, except per share amounts)

Three Months Ended – July 3, 2026Three Months Ended – July 4, 2025Nine Months Ended – July 3, 2026Nine Months Ended – July 4, 2025
GROSS PROFIT RECONCILIATIONRevenues, net210.5203636.1615.7
GROSS PROFIT RECONCILIATIONGross profit76.767.5219.1212.7
GROSS PROFIT RECONCILIATIONAmortization of intangible assets0.50.51.71.6
GROSS PROFIT RECONCILIATIONNon-GAAP gross profit77.268220.8214.3
GROSS PROFIT RECONCILIATIONGross margin %36.4%33.334.4%34.5
GROSS PROFIT RECONCILIATIONNon-GAAP gross margin %36.7%33.534.7%34.8
SELLING, GENERAL, AND ADMINISTRATIVE EXPENSE RECONCILIATIONSelling, general, and administrative30.632.999.399.3
SELLING, GENERAL, AND ADMINISTRATIVE EXPENSE RECONCILIATIONAmortization of intangible assets0.50.51.41.3
SELLING, GENERAL, AND ADMINISTRATIVE EXPENSE RECONCILIATIONRestructuring charges0.40.22.1
SELLING, GENERAL, AND ADMINISTRATIVE EXPENSE RECONCILIATIONNon-ordinary course litigation0.61.76.75.1
SELLING, GENERAL, AND ADMINISTRATIVE EXPENSE RECONCILIATIONOther non-operational costs0.10.30.10.3
SELLING, GENERAL, AND ADMINISTRATIVE EXPENSE RECONCILIATIONNon-GAAP selling, general, and administrative expense29.43090.990.5
OPERATING EXPENSE RECONCILIATIONTotal operating expenses53.9148.2166.5260.1
OPERATING EXPENSE RECONCILIATIONAmortization of intangible assets0.50.51.41.3
OPERATING EXPENSE RECONCILIATIONRestructuring charges0.40.22.1
OPERATING EXPENSE RECONCILIATIONImpairment of goodwill93.993.9
OPERATING EXPENSE RECONCILIATIONNon-ordinary course litigation0.61.76.75.1
OPERATING EXPENSE RECONCILIATIONOther non-operational costs0.10.30.10.3
OPERATING EXPENSE RECONCILIATIONNon-GAAP operating expense52.751.4158.1157.4

Income Statement

Three Months Ended — (Unaudited) (In millions, except per share amounts)

Three Months Ended – July 3, 2026Three Months Ended – July 4, 2025Nine Months Ended – July 3, 2026Nine Months Ended – July 4, 2025
OPERATING INCOME (LOSS) RECONCILIATIONOperating income (loss)22.8-80.752.6-47.4
OPERATING INCOME (LOSS) RECONCILIATIONAmortization of intangible assets (includes amortization impacts to cost of revenues)113.12.9
OPERATING INCOME (LOSS) RECONCILIATIONRestructuring charges (includes restructuring impact to cost of revenues)0.40.22.1
OPERATING INCOME (LOSS) RECONCILIATIONImpairment of goodwill93.993.9
OPERATING INCOME (LOSS) RECONCILIATIONNon-ordinary course litigation0.61.76.75.1
OPERATING INCOME (LOSS) RECONCILIATIONOther non-operational costs (includes other non-operational impacts to cost of revenues)0.10.30.10.3
OPERATING INCOME (LOSS) RECONCILIATIONTotal operating income adjustments1.797.310.1104.3
OPERATING INCOME (LOSS) RECONCILIATIONNon-GAAP operating income24.516.662.756.9
OPERATING INCOME (LOSS) RECONCILIATIONOperating margin %10.8%-39.8%8.3%-7.7%
OPERATING INCOME (LOSS) RECONCILIATIONNon-GAAP operating margin %11.6%8.2%9.9%9.2%
INCOME (LOSS) BEFORE TAXES RECONCILIATIONIncome (loss) before taxes16.2-86.613.6-73.3
INCOME (LOSS) BEFORE TAXES RECONCILIATIONTotal operating income adjustments1.797.310.1104.3
INCOME (LOSS) BEFORE TAXES RECONCILIATIONRestructuring charges-0.6-0.6
INCOME (LOSS) BEFORE TAXES RECONCILIATION(Gain) loss from equity-method investments-0.2-1.44.32.2

Income Statement

Three Months Ended — (Unaudited) (In millions, except per share amounts)

Three Months Ended – July 3, 2026Three Months Ended – July 4, 2025Nine Months Ended – July 3, 2026Nine Months Ended – July 4, 2025
NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATIONNet income (loss) attributable to Varex15.7-89.19.9-82.5
NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATIONTotal income before taxes adjustments1.595.224.4106.2
NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATIONEffective tax rate on non-GAAP adjustments %253.3%0.8%17.2%-0.4%
NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATIONTax effect on non-GAAP adjustments-3.8-0.8-4.20.4
NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATIONNon-GAAP net income13.45.330.124.1
NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATIONNon-GAAP net income adjusted for interest add-back13.45.330.124.1
NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATIONDiluted net income (loss) per share0.37-2.150.23-2
NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATIONNon-GAAP diluted net income per share0.310.130.710.58
ADJUSTED EBITDA RECONCILIATIONNet income (loss) attributable to Varex15.7-89.19.9-82.5
ADJUSTED EBITDA RECONCILIATIONInterest expense5.89.421.527.5
ADJUSTED EBITDA RECONCILIATIONIncome tax expense0.32.53.38.8
ADJUSTED EBITDA RECONCILIATIONDepreciation5.95.817.317.6
ADJUSTED EBITDA RECONCILIATIONAmortization1.113.32.9
ADJUSTED EBITDA RECONCILIATIONShare-based compensation3.83.711.611.6
ADJUSTED EBITDA RECONCILIATIONRestructuring charges-0.20.21.5
ADJUSTED EBITDA RECONCILIATIONImpairment of goodwill93.993.9
ADJUSTED EBITDA RECONCILIATIONNon-ordinary course litigation0.61.76.75.1
ADJUSTED EBITDA RECONCILIATION(Gain) loss from equity-method investments-0.2-1.44.32.2
ADJUSTED EBITDA RECONCILIATIONOther non-operational costs0.10.210.10.6
ADJUSTED EBITDA RECONCILIATIONAdjusted EBITDA33.127.588.289.2

Income Statement

INCOME BEFORE TAXES RECONCILIATION (in millions)

Q1 2025Q2 2025Q3 2025Q4 2025FY 2025
Non-GAAP income before taxes (as reported)5.814.91017.848.5
Loss (income) from equity-method investments1.71.9-1.40.12.3
Non-GAAP income before taxes (as adjusted)7.516.88.617.950.8

Income Statement

INCOME TAX EXPENSE RECONCILIATION (in millions)

Q1 2025Q2 2025Q3 2025Q4 2025FY 2025
Non-GAAP income tax expense (as reported)2.73.22.42.510.8
Tax effect on non-GAAP adjustment-0.31.1-0.9-0.4-0.5
Non-GAAP income tax expense (as adjusted)32.13.32.911.3

Income Statement

NET INCOME (LOSS) AND DILUTED NET INCOME (LOSS) PER SHARE RECONCILIATION (In millions, except per share amounts)

Q1 2025Q2 2025Q3 2025Q4 2025FY 2025
Non-GAAP net income (as reported)2.911.57.615.337.3
Loss (income) from equity-method investments1.71.9-1.40.12.3
Tax effect on non-GAAP adjustment-0.31.1-0.9-0.4-0.5
Non-GAAP net income (as adjusted)4.314.55.31539.1
Non-GAAP net income adjusted for interest add-back (as reported)2.913.17.615.337.3
Loss (income) from equity-method investments1.71.9-1.40.12.3
Tax effect on non-GAAP adjustment-0.31.1-0.9-0.4-0.5
Non-GAAP net income adjusted for interest add-back (as adjusted)4.316.15.31539.1
Diluted shares41.151.241.541.841.4
Diluted EPS (as reported)0.070.260.180.370.9
Diluted EPS (as adjusted)0.10.310.130.360.94

Balance Sheet

July 3, 2026 — (Unaudited) (In millions, except share and per share amounts)

July 3, 2026October 3, 2025
Current assets:Cash and cash equivalents99.2145
Current assets:Marketable securities010.1
Current assets:Accounts receivable, net of allowance for credit losses of $1.9 million and $2.1 million at July 3, 2026 and October 3, 2025, respectively144.7156.6
Current assets:Inventories, net347.1299.4
Current assets:Prepaid expenses and other current assets42.130.7
Current assets:Total current assets633.1641.8
Current assets:Property, plant, and equipment, net169.3157.8
Current assets:Goodwill197.6198.4
Current assets:Intangible assets, net12.414
Current assets:Investments in privately-held companies20.224.5
Current assets:Deferred tax assets22.9
Current assets:Operating lease assets27.729.4
Current assets:Other assets37.738.6
Current assets:Total assets1,1001,107.4
Current liabilities:Accounts payable83.569.9
Current liabilities:Accrued liabilities and other current liabilities72.698.4
Current liabilities:Current operating lease liabilities4.54.4
Current liabilities:Current maturities of long-term debt, net18.21.5
Current liabilities:Deferred revenues8.613
Full release

“can,” “should,” “would,” “could,” “estimate,” “may,” “intend,” and “potential,” or similar statements are forward-looking statements that involve risks and uncertainties that could cause the company's actual results and the outcome and timing of certain events to differ materially from those projected or management’s current expectations. While forward-looking statements are based on assumptions and analyses made by management of Varex that it believes to be reasonable under the circumstances, actual results and developments will depend on a number of risks and uncertainties which could cause actual results, performance, and financial condition to differ materially from such expectations. Such risks and uncertainties include: the ability of the parties to consummate the proposed transaction with Teledyne on anticipated terms and timing or at all, including obtaining stockholder and regulatory approvals and other conditions to the completion of the transaction; changes in import/export regulatory regimes, tariffs, trade wars, and national policies, including exemptions thereto; reduction in or loss of business of one or more of the company's limited original equipment manufacturing customers; global, regional, and country-specific economic instability, shifting political environments, changing tax treatment, tariffs, trade wars, and other risks associated with international manufacturing, operations and sales; loss of business to, and an inability to effectively compete with, competitors; pricing pressures and other factors that could result in market erosion or loss of customers; failure to meet customers’ needs and demands; supply chain disruptions resulting in delayed product delivery, and increased costs as a result of reliance on a limited number of suppliers for certain key components; disruption of critical information systems or material breaches in the security of such systems; inability to maintain or defend intellectual property rights, and cost associated with protecting the company's intellectual property and defending such rights and defending against infringement claims; non-compliance with regulations applicable to marketing, manufacturing, labeling, and distributing the company's... (truncated) imposed by operating and financial restrictions of the company's debt financing agreements; the financial results of the company's equity method investments and joint ventures, and the other risks listed from time to time in the company's filings with the U.S. Securities and Exchange Commission. Any forward-looking statement made by us in this news release speaks only as of the date on which it is made. Factors or events that could cause the company's actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. Varex assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events, or otherwise.

Varex has not filed its Form 10-Q for the third quarter of fiscal year 2026. All financial results described here should be considered preliminary and are subject to change to reflect any necessary adjustments or changes in accounting estimates that are identified prior to the time Varex files its Form 10-Q.

# # #

For Information Contact:

Sam Maheshwari

Chief Financial Officer

Varex Imaging Corporation

801.973.1574 | investors@vareximaging.com

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.